These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24643004)

  • 1. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
    PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
    Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
    J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
    Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.
    Delang L; Vliegen I; Froeyen M; Neyts J
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4103-13. PubMed ID: 21709100
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
    Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM
    Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
    Lin C; Lin K; Luong YP; Rao BG; Wei YY; Brennan DL; Fulghum JR; Hsiao HM; Ma S; Maxwell JP; Cottrell KM; Perni RB; Gates CA; Kwong AD
    J Biol Chem; 2004 Apr; 279(17):17508-14. PubMed ID: 14766754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
    Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
    Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
    Flores MV; Strawbridge J; Ciaramella G; Corbau R
    Biochim Biophys Acta; 2009 Oct; 1794(10):1441-8. PubMed ID: 19505593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
    Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
    Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J
    Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
    Lin K; Perni RB; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2006 May; 50(5):1813-22. PubMed ID: 16641454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system.
    Cheng G; Chan K; Yang H; Corsa A; Pokrovskii M; Paulson M; Bahador G; Zhong W; Delaney W
    Antimicrob Agents Chemother; 2011 May; 55(5):2197-205. PubMed ID: 21357305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
    Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
    Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.